What Would Be The Advantage Of Sorafenib Over Thereasphere For Liver Cancer?
My husband has primary liver cancer. He has had two ThereaSphere treatments which have shrunk the tumour from 10.4 by 9.1 to 6.7 by 7.2. They are considering Sorafenib as a possible treatment as opposed to continuing with ThereaSphere. His liver function is good. What would be the advantages of Sorafenib over continuing with ThereaSphere?
Sorafenib is a type of targeted therapy known as a kinase inhibitor.
Kinases are proteins on or near the surface of a cell that transmit important signals to the cell’s control center. Sorafenib blocks several kinase proteins that either prompt tumor cells to grow or help form new blood vessels (angiogenesis) to feed the tumor. By blocking these proteins, sorafenib can help stop the growth of cancer cells. Sorafenib in liver cancer showed improvement in median overall survival of 44% Both median survival and time to progression showed 3-month improvements. There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Regards Dr De
I find this answer helpful
You found this answer helpful
Note: For further queries related to kidney problems Click here.
Disclaimer: These answers are for your information only and not intended to replace your relationship with your treating physician.
This is a short, free answer.
For a more detailed, immediate answer, try our premium service
[Sample answer]
We use cookies in order to offer you most relevant experience and using this website you acknowledge that you have already read and understood our
Privacy Policy
What Would Be The Advantage Of Sorafenib Over Thereasphere For Liver Cancer?
Sorafenib is a type of targeted therapy known as a kinase inhibitor. Kinases are proteins on or near the surface of a cell that transmit important signals to the cell’s control center. Sorafenib blocks several kinase proteins that either prompt tumor cells to grow or help form new blood vessels (angiogenesis) to feed the tumor. By blocking these proteins, sorafenib can help stop the growth of cancer cells. Sorafenib in liver cancer showed improvement in median overall survival of 44% Both median survival and time to progression showed 3-month improvements. There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Regards Dr De